Compare SLI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | BBNX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 493.1M |
| IPO Year | 2011 | 2025 |
| Metric | SLI | BBNX |
|---|---|---|
| Price | $2.57 | $19.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $5.25 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $1.91 | $8.80 |
| 52 Week High | $6.40 | $32.71 |
| Indicator | SLI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 65.86 |
| Support Level | $2.13 | $9.34 |
| Resistance Level | $2.67 | $32.52 |
| Average True Range (ATR) | 0.13 | 1.19 |
| MACD | 0.04 | 0.33 |
| Stochastic Oscillator | 55.47 | 86.87 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.